**CARE Checklist of information to include when writing a case report**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Topic** | **Item No** | **Checklist item description** | **Reported on Page Number/Line Number** | **Reported on Section/Paragraph** |
| Title | 1 | The diagnosis or intervention of primary focus followed by the words “case report” | 1 |  |
| Key Words | 2 | 2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" | 32 |  |
| Abstract  (Structured summary) | 3a | Background: state what is known and unknown; why the case report is unique and what it adds to existing literature. | 12-14 |  |
| 3b | Case Description: describe the patient’s demographic details, main symptoms, history, important clinical findings, the main diagnosis, interventions, outcomes and follow-ups. | 15-26 |  |
| 3c | Conclusions: summarize the main take-away lesson, clinical impact and potential implications. | 27-31 |  |
| Introduction | 4 | One or two paragraphs summarizing why this case is unique **(may include references)** | 34-46 |  |
| Patient Information | 5a | De-identified patient specific information | 48-54 |  |
| 5b | Primary concerns and symptoms of the patient | 54-57 |  |
| 5c | Medical, family, and psycho-social history including relevant genetic information | 48-53 |  |
| 5d | Relevant past interventions with outcomes | 49-53 |  |
| Clinical Findings | 6 | Describe significant physical examination (PE) and important clinical findings | 64-66 |  |
| Timeline | 7 | Historical and current information from this episode of care organized as a timeline | 67-72 |  |
| Diagnostic Assessment | 8a | Diagnostic testing (such as PE, laboratory testing, imaging, surveys). | 67-70 |  |
| 8b | Diagnostic challenges (such as access to testing, financial, or cultural) | 101-103 |  |
| 8c | Diagnosis (including other diagnoses considered) | 104-122 |  |
| 8d | Prognosis (such as staging in oncology) where applicable | 104-111 |  |
| Therapeutic Intervention | 9a | Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) | 114-117 |  |
| 9b | Administration of therapeutic intervention (such as dosage, strength, duration) | 113-114 |  |
| 9c | Changes in therapeutic intervention (with rationale) | 104-117 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Follow-up and Outcomes | 10a | Clinician and patient-assessed outcomes (if available) | NA |  |
| 10b | Important follow-up diagnostic and other test results | 123-126 ; 139-142 |  |
| 10c | Intervention adherence and tolerability (How was this assessed?) | 104-111 |  |
| 10d | Adverse and unanticipated events | 127-130 |  |
| Discussion | 11a | A scientific discussion of the strengths AND limitations associated with this case report | 149-188 |  |
| 11b | Discussion of the relevant medical literature **with references** | 149-188 |  |
| 11c | The scientific rationale for any conclusions (including assessment of possible causes) | 190-193 |  |
| 11d | The primary “take-away” lessons of this case report (without references) in a one paragraph conclusion | 191-193 |  |
| Patient Perspective | 12 | The patient should share their perspective in one to two paragraphs on the treatment(s) they received | NA |  |
| Informed Consent | 13 | Did the patient give informed consent? Please provide if requested | **Yes x** | **No** |

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.